Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance

(2015) Ji Miao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Positive correlation of plasma PCSK9 levels with HbA1cin patients with type 2 diabetes

(2015) Sheng-Hua Yang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

(2015) Yuichi J. Shimada et al.   EUROPEAN HEART JOURNAL

A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA–SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts

(2015) Marie-Soleil Gauthier et al.   METHODS

Type 1 Diabetes Mellitus and Cardiovascular Disease

(2014) Sarah D. de Ferranti et al.   CIRCULATION

Clinical aspects of PCSK9

(2011) Bertrand Cariou et al.   ATHEROSCLEROSIS

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes

(2011) Bruno Vergès et al.   ATHEROSCLEROSIS

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

(2010) Bertrand Cariou et al.   ATHEROSCLEROSIS

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

(2008) Thilina Dewpura et al.   FEBS Journal

Diabetes alters LDL receptor and PCSK9 expression in rat liver

(2007) Melissa Niesen et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS